Backgrounds/Aims: Long-term immunosuppression regimens after liver transplantation (LT) are rarely reported in detail. We aimed to provide information on actual long-term immunosuppression regimens through this cross-sectional study. Methods: Our institutional LT database was searched for adult patients who underwent primary LT operation from 2000 to 2016. We identified 3620 live recipients with actual information on immunosuppressive agent use for 1-17 years. Results: The study cohort was divided into 7 groups according to posttransplantation period. The immunosuppressive agents used at the cross-sectional review period were tacrolimus in 2884 (79.7%), cyclosporine in 445 (12.3%), mycophenolate mofetil in 2007 (55.4%), and everolimus in 138 (3.8%) recipients. There was no marked difference in immunosuppressive agent use according to pretransplantation liver malignancy or type of LT operation. Tacrolimus, cyclosporine, mycophenolate mofetil, and everolimus were used in 97.4%, 1.8%, 60.9%, and 9.2%, respectively, in the year 2 group; 94.1%, 3.9%, 51.6%, and 8.3%, respectively, in the year 3 group; 87.3%, 8.4%, 68.9%, and 4.8%, respectively, in the year 4-5 group; 78.2%, 12.9%, 64.6%, and 3.0%, respectively, in the year 6-7 group; 76.9%, 10.8%, 58.8%, and 2.4%, respectively, in the year 8-10 group; 66.7%, 22.4%, 43.4%, and 1.5%, respectively, in the year 11-15 group; and 73.8%, 15.4%, 32.9%, and 1.7%, respectively, in the year ≥15 group. Conclusions: Tacrolimus and mycophenolate mofetil are the primary immunosuppressive agents after LT, and the indications for everolimus have started to increase at our institution. We believe our results will help establish tailored long-term immunosuppression regimens. 
INTRODUCTION
Liver transplantation (LT) requires lifelong immunosuppression (IS) unless the patient acquires operational tolerance. Several kinds of immunosuppressive agents (ISAs) have been administered after LT, and every LT center usually has its own IS regimen protocols. Nearly all IS regimen protocols for LT include calcineurin inhibitor (CNI), mycophenolate mofetil (MMF), and steroid.
Steroid dose is usually tapered off within short periods or intentionally omitted. Mammalian target of rapamycin (mTOR) inhibitor is increasingly administered as indicated for renal dysfunction or malignancy. IS regimen protocols are often summarized in published clinical studies from each institution; however, the complete details of institutional IS regimens are only occasionally reported. 1, 2 Especially for long-term IS regimens after LT, actual details are rarely reported.
The purpose of this study was to provide information on actual long-term IS regimens used in a high-volume LT center through a cross-sectional study in 3620 adult LT recipients.
MATERIALS AND METHODS

Study design and patient selection
This is a cross-sectional study on the actual long-term use of ISAs in adult LT recipients. We set the timing of cross-sectional review during 2 months from December 2017 to January 2018.
The LT database at our institution was searched to identify adult patients who underwent primary LT during 
Institutional IS regimen protocols
The peritransplantation primary IS protocols used for adult LT recipients at our institution consisted of interleukin-2 receptor inhibitor, intraoperative steroid bolus (5-10 mg/kg), intravenous or oral CNI and corticosteroid recycling beginning on day 1, and adjunctive MMF for patients showing CNI-associated adverse effects or for IS augmentation. For the control of CNI-associated adverse effects, tacrolimus and cyclosporine were occasionally exchanged. There were no differences in IS regimens between living-donor and deceased-donor LTs. Corticosteroid was rapidly tapered off within the first 3 months.
The target 12-hour trough concentration of tacrolimus was around 10-15 ng/ml for the first 1 month, 8-10 ng/ml within the first year, 5-8 ng/ml at 2-3 years, 5 ng/ml at 4-5 years, 3-5 ng/ml at 6-10 years, and 2-3 ng/ml after 10 years. When MMF was used for CNI sparing, the target tacrolimus concentration was reduced to half or less.
The detailed target trough levels of tacrolimus with and without MMF relative to the posttransplantation period have been summarized previously.
1,2
For MMF monotherapy, the target mycophenolic acid (MPA) level was set to at least 2-3 ng/ml and MMF dosage was adjusted according to the degree of renal dysfunction and MPA therapeutic drug monitoring (TDM). 3, 4 Concerning mTOR inhibitors, only everolimus is currently covered for LT recipients by the Korean social health insurance program. Its main indications at our institution include hepatocellular carcinoma (HCC) recurrence, de novo malignancy, and renal dysfunction.
Intentional weaning off of all ISAs was not considered to date at our institution.
Stratification of LT recipients according to posttransplantation period As the recipient conditions at the peritransplantation period are diverse, the IS regimens are also highly variable.
Thus, we did not include IS regimens during the first 1 year in the present analysis.
We divided the 3620 recipients into 7 groups according to the posttransplantation period, as follows: second year The clinical profiles of these 7 groups are summarized in (Fig. 4) . The ISA use was very similar between these 2 groups (p≥0.73).
Statistical analysis
DISCUSSION
The results of this study revealed the changing trends in the use of IS regimens during ＞10 years, providing important insights into the recent changes in IS regimens and long-term ISA use at our institution.
Tacrolimus is nearly completely replacing cyclosporine.
The proportion of cyclosporine use was 15.4% in the year ≥15 group, but it was gradually reduced and finally lowered to 1.8% in the year 2 group. Currently, cyclosporine is administered only when tacrolimus is intolerable because of serious adverse effects. Previously, cyclosporine was preferentially prescribed to recipients with hepatitis C virus infection for weak background reasons; 5 however, the recent introduction of potent direct-acting antiviral agents has led to a change in such a preference. [6] [7] [8] [9] One of the most recognizable results was the highly sustained proportion of MMF use. In the year 2 group, MMF was administered to 60.9% of patients, mostly com- however, it has also revealed a trend toward lower survival rates in non-HCC recipients. diabetes mellitus, and hyperlipidemia, the actual advantage of once-daily tacrolimus seemed to be lower than expected in the current Korean setting. 26, 27 The risk of acute rejection decreases as the posttransplantation period passes; however, subclinical pathological abnormalities emerge in a non-negligible number of recipients even after 10 years. Thus, the role of late liver biopsy after 10 years in LT recipients seems to be a matter of concern. [28] [29] [30] It is still unknown whether augmented IS can prevent or reduce the risk of such subclinical pathological abnormalities; however, we believe that a too low IS dose is not beneficial even after post-transplantation 10 years. Thus, we believe that it is better to continually maintain the IS regimen after posttransplantation 10 years. After 10 years of LT, around 20% of our recipients still receive the tacrolimus-MMF combination instead of CNI alone. A considerable proportion of these patients may be eligible for CNI monotherapy; however, we also believe that a combination of very low-dose tacrolimus and low-dose MMF is beneficial to prevent de novo malignancy.
Thus far, MMF is known to have a neutral effect on HCC recurrence. 23 Recently, it was reported that MMF monotherapy is associated with a lower risk of cancer in LT recipients compared with maintenance IS with CNIs. 31 In fact, MMF is an ISA with potential anti-cancer activity.
MMF inhibits tumor cell growth and angiogenesis in vitro, although this effect has not translated to clinical anti-cancer benefit. 32 In a single-center study, the combination of CNI and MMF in kidney transplant recipients was associated with a higher risk of malignancy than were other IS regimens. 33 In contrast with these results, multicenter studies have shown that renal, cardiac, and liver transplant recipients who take MMF have a lower or at least not higher risk of malignancy than those without MMF therapy. [34] [35] [36] We identified that the long-term IS regimen was not different between recipients of deceased-donor and living-donor LTs. In fact, pretransplantation HCC was more common in living-donor LT recipients, whereas renal dysfunction was more common in deceased-donor LT recipients. We presume that these differences in patient characteristics led to the reciprocal offsetting of the differences in ISA selection.
The present study has several limitations. First, this is a retrospective single-center study with a cross-sectional review covering a short-term period. Second, we did not analyze the TDM concentration of each ISA and the intra-individual changes of ISAs because we have presented these findings previously. [1] [2] [3] [4] Third, we did not separately present the profiles of patients who were alive at the time of data collection after the development of HCC recurrence or de novo malignancy because they will be presented in future reports of ongoing studies. The strong point of this study is that there is no case with lost data because all study patients are alive and regularly followed up at our institution.
In conclusion, we consider tacrolimus and MMF as the primary ISAs after LT and the indications for mTOR inhibitor have started to increase. We believe that our results will help establish tailored long-term IS regimen protocols in new or small-volume LT centers.
